Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

52Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.

Cite

CITATION STYLE

APA

Khalaj-Hedayati, A., Chua, C. L. L., Smooker, P., & Lee, K. W. (2020, January 1). Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement. Influenza and Other Respiratory Viruses. Blackwell Publishing Ltd. https://doi.org/10.1111/irv.12697

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free